Lifeward Secures $5.58M in Initial Tranche of $11.16M Convertible Note and Warrant Financing at a Discount
LFWD has more than doubled off its 52-week low of $4.14 on elevated volume (4.4× avg).
Summary
Lifeward Ltd. has secured an initial $5.58 million in a highly dilutive convertible note and warrant financing, with an additional $5.58 million contingent on performance, to address its 'going concern' warning.
Key Events · Financing and Capital Events · LFWD
-
Secured $5.58M Initial Financing
Lifeward Ltd. received an initial $5.58 million from a new securities purchase agreement, consisting of senior secured convertible notes and warrants.
-
Potential Additional $5.58M Contingent on Performance
A second tranche of $5.58 million is available, subject to achieving a 150% increase in ReWalk Unit Sales or the stock price exceeding $13.80 for 10 consecutive trading days.
-
Dilutive Terms at a Discounted Price
The conversion and exercise price for the notes and warrants is $5.40 per share, a significant discount compared to the current stock price of $8.45. This is highly dilutive for existing shareholders.
-
Addresses 'Going Concern' Warning
This financing provides critical capital for the company, which had previously issued a 'going concern' warning in its Q1 2026 earnings report and 10-Q filing.
Analysis · LFWD · Industrial Applications And Services
Lifeward Ltd. has secured a critical financing package totaling up to $11.16 million, with an initial $5.58 million received immediately. This financing, structured as senior secured convertible notes and accompanying warrants, is crucial for the company, which recently reaffirmed a 'going concern' warning. However, the terms are highly dilutive for existing shareholders, as the conversion and exercise price is set at $5.40 per share, a significant discount to the current market price of $8.45. An additional $5.58 million is contingent on achieving specific performance milestones, such as a 150% increase in ReWalk Unit Sales or the stock price exceeding $13.80 for ten consecutive trading days. The notes carry an 8% interest rate, escalating to 15% upon default, and the issuance of underlying shares is subject to a 19.99% exchange cap without further shareholder approval. Oramed Pharmaceuticals Inc., a major existing shareholder, is involved as a collateral agent in this transaction, indicating their continued support but also the challenging nature of the capital raise.
At the time of this filing, LFWD was trading at $8.45 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $23.8M. The 52-week trading range was $4.14 to $10.98. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.